William E. lv  Delaney net worth and biography

William Delaney Biography and Net Worth

William Delaney, PhD joined Assembly as Chief Scientific Officer, Virology in May 2020. Prior to joining Assembly, he most recently served as Executive Director, Biology at Gilead. During his 20-year career at the company, he headed the Viral Hepatitis & Herpes Discovery Biology Groups and served as the Research Therapeutic Area Head for HBV. He began his career as a Research Scientist, Clinical Virology at Gilead and later transitioned into Drug Discovery where he held positions of increasing responsibility. Over the course of his career, he has contributed to the development of several marketed products, including Hepsera®, Viread®, and Vemlidy® for HBV and Sovaldi®, Harvoni®, Epclusa®, and Vosevi® for HCV. He earned a BS in Biotechnology from the University of Delaware and a PhD in Cell and Molecular Biology from the Penn State College of Medicine. In addition, he was a Postdoctoral Fellow at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Department of Research & Molecular Development.

What is William E. lv Delaney's net worth?

The estimated net worth of William E. lv Delaney is at least $84,694.40 as of May 31st, 2022. Dr. Delaney owns 6,368 shares of Assembly Biosciences stock worth more than $84,694 as of March 29th. This net worth approximation does not reflect any other assets that Dr. Delaney may own. Additionally, Dr. Delaney receives a salary of $664,400.00 as Insider at Assembly Biosciences. Learn More about William E. lv Delaney's net worth.

How old is William E. lv Delaney?

Dr. Delaney is currently 52 years old. There are 2 older executives and no younger executives at Assembly Biosciences. The oldest executive at Assembly Biosciences is Mr. Thomas E. Rollins, Executive Officer, who is 68 years old. Learn More on William E. lv Delaney's age.

What is William E. lv Delaney's salary?

As the Insider of Assembly Biosciences, Inc., Dr. Delaney earns $664,400.00 per year. The highest earning executive at Assembly Biosciences is Mr. Jason A. Okazaki, CEO, President & Director, who commands a salary of $869,280.00 per year. Learn More on William E. lv Delaney's salary.

How do I contact William E. lv Delaney?

The corporate mailing address for Dr. Delaney and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on William E. lv Delaney's contact information.

Has William E. lv Delaney been buying or selling shares of Assembly Biosciences?

William E. lv Delaney has not been actively trading shares of Assembly Biosciences during the past quarter. Learn More on William E. lv Delaney's trading history.

Who are Assembly Biosciences' active insiders?

Assembly Biosciences' insider roster includes William Delaney (Insider), John McHutchison (CEO), and Timothy Springer (Director). Learn More on Assembly Biosciences' active insiders.

Are insiders buying or selling shares of Assembly Biosciences?

During the last twelve months, Assembly Biosciences insiders bought shares 1 times. They purchased a total of 24,999 shares worth more than $233,990.64. During the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 4,812 shares worth more than $54,687.84. The most recent insider tranaction occured on January, 17th when Major Shareholder Alexander Schornstein bought 24,999 shares worth more than $233,990.64. Insiders at Assembly Biosciences own 4.1% of the company. Learn More about insider trades at Assembly Biosciences.

Information on this page was last updated on 1/17/2024.

William E. lv Delaney Insider Trading History at Assembly Biosciences

See Full Table

William E. lv Delaney Buying and Selling Activity at Assembly Biosciences

This chart shows William E. Iv Delaney's buying and selling at Assembly Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Assembly Biosciences Company Overview

Assembly Biosciences logo
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $13.30
Low: $13.02
High: $13.50

50 Day Range

MA: $12.10
Low: $10.20
High: $13.58

2 Week Range

Now: $13.30
Low: $7.69
High: $20.04

Volume

30,210 shs

Average Volume

18,158 shs

Market Capitalization

$72.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56